Taking Care of Mommy and the Kiddos View More
Amicus Therapeutics, Inc. is working to make the world a better place for children and adults suffering from an array of devastating genetic diseases.
The global biotechnology company was founded in 2002 and went public in 2007. Amicus Therapeutics is currently headed up by Chairman of the Board and Chief Executive Officer (CEO) John F. Crowley whose involvement in biotechnology research began after two of his children were diagnosed in 1998 with Pompe disease. The disorder is a severe and many times fatal neuromuscular disease.
Amicus Therapeutics is a frontrunner in the field of advanced therapies to treat rare and orphan diseases that are debilitating and sometimes fatal for the people who suffer from them (Weekly Opinion). The company’s latest development, Migalastat, is a customized medicine that will be used to treat patients suffering from Fabry Disease. The medicine is personalized to fit their exact genetic diagnosis.
Amicus Therapeutics is also in the process of developing medicines and platform technologies to combat diseases like Fabry, which is a lysosomal storage disorder, and Pompe Disease, which is an inherited disorder caused by the buildup of glycogen in the person’s cells throughout their body. People, like John Crowley’s two children, suffer the consequences of the body’s impaired ability to function properly as the glycogen builds up in their bodies’ cells. Amicus Therapeutics is working every day to create the medicines that will help combat these disorders and many others, along with lessening the effects of these diseases so people can function normally and without pain.
The staff at Amicus Therapeutics works to put the needs of the patients in the rare disease community first by providing outstanding clinical programs by using inventive and innovative scientific technologies.
The staff of Amicus Therapeutics business-focused but science-driven, always striving to deliver the best treatments for patients (https://finance.yahoo.com/quote/FOLD?ltr=1). Amicus Therapeutics company’s advanced pipeline of products and platform techniques are constantly being perfected with a passion for the patients the company serves.